logo

Diseases and Drugs

Share

fda oct23 On October 22, the FDA approved Gilead's (GILD) Veklury (remdesivir), the first drug for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Let's take a look at the companies that await a ruling from the FDA in November.

drug sept25 As of this writing, the FDA has approved 40 novel drugs so far this year compared to just 27 during the same period (Jan-Sep) last year. Now, let's take a look at the biotech stocks facing FDA decision in October.

russia aug25 So far this year, 36 novel drugs have passed muster with the FDA compared to 26 during the same period (Jan- Aug) in 2019. Let's take a look at the companies that await a ruling from the FDA in September.

inqovi july24 As another month comes to a close, it's time to take a look back at some of the top news stories of July related to FDA approvals and look ahead at what's coming next over the horizon.

fdadecision april28 25jun20 The first half of 2020 looks set to end on an encouraging note for new drug approvals despite the ongoing coronavirus pandemic. Let's take a look at the biotech stocks facing FDA decision in July.

astrazeneca june12 When will a safe and effective vaccine for COVID-19 be ready? Vaccine makers are racing against time to develop a vaccine to fight the novel coronavirus. There are more than 130 candidate vaccines in development against SARS-COV-2, the pathogen that causes COVID-19, of which 10 have moved into clinical trials.

solenopws june09 Although there are FDA approved therapies for the treatment of growth failure in children with PWS, say, Pfizer's (PFE) recombinant human growth hormone Genotropin (somatropin) and Sandoz/Novartis' Omnitrope, a biosimilar for Genotropin, there is no approved therapy yet to treat hyperphagia or excessive eating, the cardinal symptom of PWS.

fda1 may22 The FDA has been focusing mainly on COVID-19-related review since March. But that said, the regulatory decision on drugs proposed for rare tumors and life-threatening diseases has not been deferred. Now, let's take a look at the biotech stocks awaiting a regulatory decision in the month of June.

lab april30 The ongoing COVID-19 pandemic has sickened over 3.25 million people and has killed 233,014 people, according to data from Johns Hopkins University.

fda2 042420 So far this year, 16 novel drugs have received FDA approval compared to 9 which were greenlighted during the same period last year. Now, let's take a look at the biotech stocks that are awaiting a regulatory decision in May 2020.

pfizer april09 Drinking too much alcohol can lead to the accumulation of fat in the liver, which in turn can lead to irreversible damage to the organ over the long run. But people who don't drink or drink very little also can develop a liver disease, which goes by the name non-alcoholic fatty liver disease, or NAFLD, a condition caused by the buildup of extra fat in liver cells.

pharma oct17 The novel coronavirus that originated in the city of Wuhan in China last December, has spread to almost all the countries, affecting millions. As of this writing, the number of confirmed cases is 1,274,346 and the death toll is 69,480.

covid april03 Currently, there are no treatments or vaccines for COVID-19. A number of companies are racing to find a treatment or vaccine for the same. What is the latest by which a vaccine for COVID-19 will be available?

coronavirusvaccine march23 While the governments, researchers, companies among others are in search of one or more treatments that can help address the deadly Coronavirus, investors are in search of investment opportunities in biotech and pharmaceutical stocks. The following are some of the companies developing drugs/vaccines for COVID-19.

Diagnostics play a key role in combating a flu pandemic because the test results not only help to know if a person has been infected by the virus but will also help to take measures to prevent the infection spread.

Follow RTT